Related Experiment Videos
Hydrocephalus following aneurysmal SAH
Insights
Combination antifibrinolytic therapy, including tranexamic acid (AMCA) and aprotinin, reduced hydrocephalus formation after subarachnoid hemorrhage compared to AMCA alone. This suggests a link between erythrocyte breakdown products and hydrocephalus development.
Area of Science:
- Neurosurgery
- Neurology
- Pharmacology
Background:
- Subarachnoid hemorrhage (SAH) frequently leads to hydrocephalus.
- Antifibrinolytic therapy is used to manage SAH complications.
- The precise mechanisms linking SAH, antifibrinolytics, and hydrocephalus remain under investigation.
Purpose of the Study:
- To compare the efficacy of two antifibrinolytic regimens in preventing hydrocephalus after SAH.
- To investigate factors influencing hydrocephalus development post-SAH.
- To explore the relationship between ischemic complications and hydrocephalus.
Main Methods:
- Two patient groups received different antifibrinolytic treatments: Group A (AMCA + aprotinin) and Group B (AMCA alone).
- Hydrocephalus formation and ischemic complications were monitored.
- Statistical analysis was performed to identify correlations between various factors and outcomes.
Main Results:
- Group A demonstrated significantly lower rates of hydrocephalus and ischemic complications compared to Group B.
- Neurological condition, hemorrhage severity, and aneurysm location influenced hydrocephalus development.
- A strong correlation was observed between preceding ischemic complications and hydrocephalus (p < 0.005).
- Antihypertensive use increased ischemic complications but did not affect hydrocephalus rates.
Conclusions:
- Combination therapy with AMCA and aprotinin appears more effective in preventing hydrocephalus post-SAH.
- Erythrocyte decomposition products are hypothesized as a key factor in the pathogenesis of cerebral ischemia and hydrocephalus after SAH.
- The study does not support periventricular ischemia as the primary cause of hydrocephalus following SAH.
Abstract:
An aneurysm-induced hydrocephalus was observed in two series of patients who were treated antifibrinolytically in different ways: A = 3 g/day of AMCA + 3 - 400,000 KIU/day of aprotinins, B = 6 g/day of AMCA. Group A showed significantly less formation of hydrocephalus and ischaemic complications. In the survey, various factors (neurological condition, number of haemorrhages, localisation of the aneurysm) play a part in the formation of the hydrocephalus following subarachnoid haemorrhage (SAH). The same is true of the high correlation with preceding severe ischaemic complications after SAH (p less than 0.005). The administration of antihypertensives leads to a significantly higher rate of ischaemic complications but does not exert an influence on the formation of hydrocephalus. It is assumed that the close relationship is the essential cause of cerebral ischaemia and development of hydrocephalus after SAH, that is, erythrocyte decomposition products which explain the observed relations between the two. The results obtained do not support the thesis of periventricular ischaemia as the cause of the development of a clinically significant hydrocephalus after SAH.